Introduction: Renal cell carcinoma (RCC) is one of the most prevalent metabolic diseases and a leading cause of utmost mortality among men globally. In spite of extensive development in technology for biomarker discovery during the last 10 years, the currently used clinical biomarkers are still unable to detect RCC at early and progression stages. Hence, the development of new and precise biomarkers is most important to improve the clinical management of RCC and reduce the level of mortality.Area covered: For the detection of RCC at an early stage; a new branch of omics technology - metabolomics - has been introduced. Mainly two techniques (mass spectrometry and nuclear magnetic resonance spectroscopy) have been exploited to execute metabolomics. Precisely, metabolomics showed promising and powerful approach to identify novel RCC biomarker. The present review discussed and the literature search to narrate the outcomes of the past 10 years of studies related to RCC pathophysiology, metabolomics, advancements, and shortcomings.Expert opinion: Although, compared to mass spectrometric tactic, nuclear magnetic resonance is moving fast to achieve the aim and in vivo application for diagnosis and management of RCC, metabolomics-based research in RCC is still in its infancy stage.
Expert review of molecular diagnostics. 2019 Dec 16 [Epub ahead of print]
Ashish Gupta, Kavindra Nath, Navneeta Bansal, Manoj Kumar
Centre of Biomedical Research, SGPGIMS Campus, Lucknow, India., Department of Radiology, University of Pennsylvania, Pheladelphia, PA, USA., Department of Urology, King George's Medical University, Lucknow, India.